Granisetron was more Effective than Ondansetron as Antiemetic in Ovarian Cancer Patients: a Randomized Controlled Trial

Objective: To determine the effectiveness of intravenous injection of granisetron compared to ondansetron in preventing nausea and vomiting, we used the MASCC Antiemesis Tool (MAT) in ovarian cancer patients undergoing paclitaxel-carboplatin chemotherapy Methods: This study was conducted as a double-blind, randomized controlled trial. The treatment group received 1 mg of granisetron, whereas the control group received 8 mg of ondansetron intravenously. Nausea and vomiting were assessed using the MAT scale at 12 hours, 24 hours, and 48 hours after chemotherapy. The differences in MAT scores between the groups were analyzed using the Mann-Whitney test. Results: A total of 60 participants were enrolled in this study. The results indicated that the MAT score at the 12-hour mark significantly differed from the 24-hour and 48-hour MAT scores (p = 0.00, p = 0.00). The MAT scores in the granisetron group at 12 hours, 24 hours, and 48 hours were statistically lower compared to the ondansetron group (p = 0.00, p = 0.00, p = 0.00). Conclusions: In conclusion, intravenous granisetron proved to be more effective than intravenous ondansetron in preventing nausea and vomiting among patients with ovarian cancer undergoing paclitaxel-carboplatin chemotherapy. © 2023 Human Kinetics, Inc.